Site Management/Investigator Payments Featured Articles

1. Can Independent Pharmacies Succeed Where Walgreens Failed? 5/21/2026

   Josh Rose, CEO of Hawthorne Health, believes independent community pharmacies may succeed where large retail chains struggled in clinical research. In this interview, Rose explains how Hawthorne is building pharmacy-based trial sites focused on underserved communities, chronic disease studies, and trusted patient relationships.

2. How Did You End Up In Clinical Research? 5/20/2026

   To commemorate Clinical Trials Day, we asked clinical researchers to share their story, answering, "How did you get into clinical research?"

3. Why Site Engagement Isn't Just A Role Anymore 5/14/2026

   GSK’s Laura O'Donnell says site engagement is no longer just a function or team, it’s an organization-wide capability. In this article, she discusses why the traditional CRA relationship model has broken down, how sponsors are using data and AI to better support sites, and why human connection still matters in an increasingly automated clinical trial environment.

4. Collaboration Isn't Sexy. That's Kind of the Point. 5/8/2026

   SCRS’s Collaborate Forward playbook isn’t about reinventing clinical trials; it’s about fixing how people work together. Based on real-world examples, the initiative shows how small, practical changes in collaboration are already improving study startup, site relationships, and operational performance.

5. The Industry Talks Access — Fabian Sandoval Builds It 5/1/2026

   Fabian Sandoval is redefining what a clinical research site looks like — building trust through community partnerships, media, and education to improve trial access and awareness long before enrollment begins.

6. The Rise — And Stall — Of Retail Pharmacy Clinical Trials 4/23/2026

   As rumors swirl that Walgreens may be reassessing its clinical trials business, this article explores a broader trend: why major retail pharmacy chains like CVS, Walmart, and Kroger have struggled to make the model work at scale.

7. What Sites, Sponsors, Vendors, And CROs Can All Agree On 4/17/2026

   Experts representing sponsors, sites, vendors, and CROS discussed at Life Sciences Future SW the pain points and the opportunities that lie ahead in clinical research.

8. Assigned Slot Allocation Offers A Fair Solution For Oncology Phase 1 Trials (Part 2) 4/10/2026

   In part two of this series on slot allocation, Nehal Lakhani, MD, Ph.D. proposes assigned slot allocation as an alternative to competitive placement and discusses how the approach might benefit patients and sites.

9. Slot Allocation Is A Problem For Patients And PIs In Phase 1 Oncology Trials (Part 1) 4/10/2026

   Given the shift in the size and scope of oncology Phase 1 trials, cohort management and slot allocation strategies must change, too. Nehal Lakhani, MD, Ph.D. explains why competitive slot allocation is no longer optimal for patients or PIs.

10. Considerations For Allergic Rhinitis Trials Are Nothing To Sneeze At 4/8/2026

    Inimmune CEO David Burkhart explains how a GSK layoff led to the formation of a new company focused on treating allergic rhinitis. Here, he shares success from the company's approach to site selection, trial design, and timing.